Cancer Center, The First Hospital of Jilin University.
Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China.
Anticancer Drugs. 2021 Apr 1;32(4):469-473. doi: 10.1097/CAD.0000000000000995.
Lung cancer is one of the most important and lethal cancers in the world. Human epidermal growth factor 2 (HER2) is a member of the erbB receptor tyrosine kinase family. The incidence of HER2 kinase domain mutations in adenocarcinoma of lung ranges from 1% to 3%. HER2 V659D mutation is located in the trans-membrane domain (TMD) with only a few cases reported before, and importantly, there were no more standard and effective ways for this kind of diseases until now. Afatinib irreversibly blocks all kinase-competent HER family members. Apatinib is one of the small-molecule oral anti-angiogenesis-targeted agents developed firstly in China, and it's a highly selective inhibition of the activity of VEGFR-2. This report presents an advanced lung adenocarcinoma patient with HER2 V659D mutation who was treated with combination of Afatinib and Apatinib. He achieved good efficacy and tolerable adverse reactions.
肺癌是全球最重要且致命的癌症之一。人类表皮生长因子 2（HER2）是 erbB 受体酪氨酸激酶家族的一员。肺腺癌中 HER2 激酶结构域突变的发生率为 1%至 3%。HER2 V659D 突变位于跨膜结构域（TMD），以前报道的病例较少，重要的是，到目前为止，针对这种疾病还没有更标准和有效的方法。阿法替尼不可逆地阻断所有具有激酶活性的 HER 家族成员。阿帕替尼是中国首先开发的小分子口服抗血管生成靶向药物之一，它高度选择性地抑制 VEGFR-2 的活性。本报告介绍了一例 HER2 V659D 突变的晚期肺腺癌患者，该患者接受阿法替尼和阿帕替尼联合治疗。他取得了良好的疗效，且不良反应可耐受。
